MEDNAX (NYSE:MD) received a $62.00 price target from analysts at Stephens in a report released on Thursday. The brokerage presently has a “buy” rating on the stock. Stephens’ price objective would suggest a potential upside of 14.94% from the company’s previous close.
A number of other research firms have also recently weighed in on MD. Zacks Investment Research raised shares of MEDNAX from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. BMO Capital Markets started coverage on shares of MEDNAX in a research note on Monday, October 16th. They set a “market perform” rating and a $46.00 target price on the stock. KeyCorp set a $51.00 target price on shares of MEDNAX and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Jefferies Group reaffirmed a “hold” rating and set a $44.00 target price on shares of MEDNAX in a research note on Friday, November 3rd. Finally, Robert W. Baird boosted their target price on shares of MEDNAX from $47.00 to $48.00 and gave the stock a “neutral” rating in a research note on Friday, November 3rd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the stock. MEDNAX presently has an average rating of “Hold” and a consensus price target of $55.08.
Shares of MEDNAX (NYSE MD) traded up $1.38 on Thursday, reaching $53.94. 1,694,384 shares of the company’s stock traded hands, compared to its average volume of 857,284. MEDNAX has a 1-year low of $40.56 and a 1-year high of $72.13. The firm has a market capitalization of $4,922.52, a P/E ratio of 15.63, a P/E/G ratio of 1.45 and a beta of 0.31. The company has a current ratio of 1.43, a quick ratio of 1.37 and a debt-to-equity ratio of 0.60.
In related news, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total value of $154,740.00. Following the sale, the insider now owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 2.40% of the company’s stock.
Several institutional investors have recently modified their holdings of MD. Fuller & Thaler Asset Management Inc. bought a new stake in shares of MEDNAX in the third quarter worth $103,000. Denali Advisors LLC bought a new stake in MEDNAX during the third quarter valued at $185,000. Meiji Yasuda Asset Management Co Ltd. boosted its position in MEDNAX by 45.3% during the third quarter. Meiji Yasuda Asset Management Co Ltd. now owns 5,230 shares of the company’s stock valued at $226,000 after acquiring an additional 1,630 shares during the last quarter. Delta Capital Management LLC bought a new stake in MEDNAX during the fourth quarter valued at $227,000. Finally, QS Investors LLC boosted its position in MEDNAX by 0.3% during the second quarter. QS Investors LLC now owns 3,812 shares of the company’s stock valued at $230,000 after acquiring an additional 12 shares during the last quarter. 98.67% of the stock is currently owned by institutional investors.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.